Luc/GFP Reporter Cell Line-AGS

AGS is a comprehensively characterized human gastric adenocarcinoma cell line, originally derived from tumor fragments of a 54-year-old Caucasian female patient who had not received prior antineoplastic therapy. Growing as an adherent, epithelial-like monolayer, AGS serves as a foundational model in gastrointestinal oncology, extensively utilized for studying gastric carcinogenesis and Helicobacter pylori pathogenesis. The Luc/GFP Reporter Cell Line - AGS advances this essential model through the stable genetic integration of a dual-reporter construct expressing both firefly luciferase (Luc) and Green Fluorescent Protein (GFP). This precise engineering endows the cells with two distinct tracking modalities: the constitutive expression of GFP provides a bright, stable fluorescent signal for direct optical detection, while the luciferase enzyme produces a highly quantifiable bioluminescent signal upon exposure to the standard substrate D-luciferin. Crucially, the genetic modification process is carefully executed to preserve the fundamental biological integrity of the parental line. The engineered cells strictly maintain their native epithelial morphology, proliferative dynamics, and complex molecular profile, providing a biologically authentic and highly traceable platform for advanced gastric cancer research.

The co-expression of luciferase and GFP transforms the AGS cell line into a highly versatile asset for both rigorous in vitro analytics and complex preclinical animal modeling. In standard laboratory environments, the robust GFP fluorescence facilitates real-time visualization of cellular morphology and enables precise isolation of specific cell populations via fluorescence-activated cell sorting (FACS). Concurrently, the luminescent output allows for highly sensitive, high-throughput quantification of cell viability, making it an ideal platform for screening novel chemotherapeutics or evaluating host-pathogen interactions during H. pylori infections. When utilized to establish subcutaneous or orthotopic gastric xenografts in immunodeficient mice, the robust luciferase emission enables highly sensitive, non-invasive bioluminescence imaging (BLI). This capability empowers researchers to visually map early tumor engraftment, track regional metastasis, and dynamically evaluate experimental therapeutic efficacy in living subjects.